RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system

Kim, Sung Wook; Kim, Na Young; Choi, Yuri; Park, Seo Hyun; Yang, Jai Myung; Shin, Sungho

doi:10.1016/j.jconrel.2010.01.009

Cited by 82 publications

(74 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our group has previously reported a matrix metalloproteinases-2 responsive hydrogel drug delivery system aiming for glioblastoma, a great option to combine with the result reported here [40, 48]. Although we have not proceed to in vivo animal experiment yet, Kim et al has shown that HER-2-specific siRNA/R 15 complexes resulted in a marked reduction of SKOV-3 xenograft tumor growth in nude mice in vivo [24]. Further study is warranted to investigate the miRNA-21 silencing efficiency mediated by anti-miR-21/R 8 complexes in vivo .…”

Section: Discussionmentioning

confidence: 94%

Arginine-rich, cell penetrating peptide–anti-microRNA complexes decrease glioblastoma migration potential

et al. 2014

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a class of gene regulators originating from non-coding endogenous RNAs. Altered expression, both up - and down-regulation, of miRNAs plays important roles in many human diseases. Correcting miRNA dysregulation by either inhibiting or restoring miRNA function may provide therapeutic benefit. However, efficient, nontoxic miRNA delivery systems are in need. Cell penetrating peptides (CPPs) have been widely exploited for protein, DNA, and RNA delivery. Few have examined CPP transfection efficiency with single stranded anti-miRNA. The R8 peptide condensed both siRNA and anti-miRNA. Greater than 50% of cells had anti-miRNA/R8 complexes associated and in these cells 68% of anti-miRNA escapes the endosome/lysosome. Single -stranded antisense miR-21 inhibitor (anti-miR-21) administered using the R8 peptide elicited efficient downstream gene upregulation. Glioblastoma cell migration was inhibited by 25% compared to the negative control group. To our knowledge, this is the first demonstration of miRNA modulation with anti-miR-21/R8, complexes which has laid the groundwork for further exploring octaarginine as intracellular anti-miRNAs carrier.

show abstract

Section: Discussionmentioning

confidence: 94%

Arginine-rich, cell penetrating peptide–anti-microRNA complexes decrease glioblastoma migration potential

et al. 2014

View full text Add to dashboard Cite

show abstract

“…These include HSA [138], transferrin [139], atelocollagen [140], poly (Pro-Hyp-Gly) [141], cholesteryl oligoarginine [142, 143], and MPG-8, a 21-residue amphipathic peptide [144]. Son et al introduced thiol groups to both VEGF siRNA and HSA to form disulfide-bonded complexes of the two.…”

Section: Polymeric Sirna Delivery Systemsmentioning

confidence: 99%

Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors

Wen

Meng

2014

J Pharm Innov

View full text Add to dashboard Cite

Small-interfering RNA (siRNA) is both a powerful tool in research and a promising therapeutic platform to modulate expression of disease-related genes. Malignant tumors are attractive disease targets for nucleic acid-based therapies. siRNA directed against oncogenes, and genes driving metastases or angiogenesis have been evaluated in animal models and in some cases, in humans. The outcomes of these studies indicate that drug delivery is a significant limiting factor. This review provides perspectives on in vivo validated nanoparticle-based siRNA delivery systems. Results of recent advances in liposomes and polymeric and inorganic formulations illustrate the need for mutually optimized attributes for performance in systemic circulation, tumor interstitial space, plasma membrane, and endosomes. Physiochemical properties conducive to efficient siRNA delivery are summarized and directions for future research are discussed.

show abstract

“…Because the short synthetic peptide ACSSSPSKHCG (TD1) and oligoarginine (R8) have been shown to facilitate efficient bio-macromolecule delivery through intact skin, [36][37][38][39] we developed a new peptide by conjugating TD1 and R8, and employed this peptide (TD1-R8), ACSSSPSKHCGGRRRRRRRR, to deliver siRNA to the skin. TD1-R8 peptide was synthesized and labeled with fluorescein isothio cyanate in vitro by Geno Biotechnology (Beijing, China).…”

Section: Determination Of Cell Viability and Melanin Production In Mementioning

confidence: 99%

MITF-siRNA Formulation Is a Safe and Effective Therapy for Human Melasma

et al. 2011

View full text Add to dashboard Cite

It is unclear whether siRNA-based agents can be a safe and effective therapy for diseases. In this study, we demonstrate that microphthalmia-associated transcription factor-siRNA (MITF-siR)-silenced MITF gene expression effectively induced a significant reduction in tyrosinase (TYR), tyrosinase-related protein 1, and melanocortin 1 receptor (MC1R) levels. The siRNAs caused obvious inhibition of melanin synthesis and melanoma cell apoptosis. Using a novel type of transdermal peptide, we developed the formulation of an MITF-siR cream. Results demonstrated that hyperpigmented facial lesions of siRNA-treated subjects were significantly lighter after 12 weeks of therapy than before treatment (P < 0.001); overall improvement was first noted after 4 weeks of siRNA treatment. At the end of treatment, clinical and colorimetric evaluations demonstrated a 90.4% lightening of the siRNA-treated lesions toward normal skin color. The relative melanin contents in the lesions and adjacent normal skin were decreased by 26% and 7.4%, respectively, after treatment with the MITF-siR formulation. Topical application of siRNA formulation significantly lightens brown facial hypermelanosis and lightens normal skin in Asian individuals. This treatment represents a safe and effective therapy for melasma, suggesting that siRNA-based agents could be developed for treating other diseases such as melanoma.

show abstract

RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system

Cited by 82 publications

References 29 publications

Arginine-rich, cell penetrating peptide–anti-microRNA complexes decrease glioblastoma migration potential

Arginine-rich, cell penetrating peptide–anti-microRNA complexes decrease glioblastoma migration potential

Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors

MITF-siRNA Formulation Is a Safe and Effective Therapy for Human Melasma

Contact Info

Product

Resources

About